Table 1.
Selected omics studies on psoriasis (PSO) and atopic dermatitis (AD)
| GEO ID | Year | Dx | Focus (# samples) | Technology | Reference |
|---|---|---|---|---|---|
| GSE16161 | 2009 | AD, PSO, NN | AD‐LS (9), PSO‐LS (15), NN (9) | HG‐U133_Plus_2 | 277 |
| GSE32924 | 2011 | AD, NN | LS (13), NL (12), NN (8) | HG‐U133_Plus_2 | 145 |
| GSE27887 | 2011 | AD | UVB, LS, NL, w0/w12, 10 pts. (35) | HG‐U133_Plus_2 | 157 |
| GSE36842 | 2012 | AD, NN | Acute/chronic, LS, NL, NN, 10 pts (39) | HG‐U133_Plus_2 | 196 |
| GSE75890 | 2016 | AD, PSO, NN | Mild ex‐/intrinsic, AD (14), PSO (9), NN (8) | HG 2.1 ST | 278 |
| GSE60709 | 2014 | AD, NN |
Epidermal shave, LS (12), NL (7), NN (14) DNA methylation, skin and blood |
Illumina HT‐12V3.0 Infinium 27K |
223 |
| GSE107361 | 2018 | AD | Infants/adults, LS (39), NL (40), NN (29) | HG‐U133_Plus_2 | 212 |
| GSE58558 | 2014 | AD | Cyclosporin A, LS, NL, w0/w2/w12 (109) | HG‐U133_Plus_2 | 158 |
| GSE59294 | 2014 | AD | Dupilumab, LS, NL, w0/w4 (40) | HG‐U133_Plus_2 | 159 |
| GSE120721 | 2015 | AD, NN | LCM, LS (15), NL (15), NN (22), epi/dermis | HG‐U133_Plus_2 | 222 |
| GSE65832 | 2015 | AD | RNA‐seq, LS (20), NL (20) | Illumina GA IIx | 279 |
| GSE81119 | 2017 | ‘AD’ mice | Mouse models of inflammation and ‘AD’ (37) | MG 1.0 ST | 280 |
| NA | 2018 | AD | Tape strip RNA‐seq, LS (11), NL (18), NN (13) | Ion Torrent | 213 |
| GSE120899 | 2018 | AD | Apremilast, LS, NL, w0/w12 (59) | HG‐U133_Plus_2 | Not published? |
| GSE99802 | 2018 | AD | Fezakinumab, LS, NL, w0/w4/w12 (302) | HG‐U133_Plus_2 | 161 |
| GSE121212 | 2019 | AD, PSO, NN | RNA‐seq, AD (27LS, 27NL), PSO (28LS, 27NL), NN (38) | Illumina GA | 334 |
| GSE14905 | 2008 | PSO, NN | LS (33), NL (28), NN (21) | HG‐U133_Plus_2 | 143 |
| GSE13355 | 2009 | PSO, NN | LS (58), NL (58), NN (64) | HG‐U133_Plus_2 | 281 |
| GSE31037 | 2011 | PSO, NN | miRNA, LS (24), NL (23), NN (20) | Illumina GA IIx | 282 |
| GSE30999 | 2012 | PSO, NN | LS (85), NL (85) | HG‐U133_Plus_2 | 283 |
| GSE26866 | 2012 | PSO | LCM, LS (20), NL (17), epi/dermis, | HG‐U133_A 2.0 | 284 |
| GSE11903 | 2009 | PSO | Etanercept, LS, NL, w0/1/2/4/12 (89) | HG‐U133_Plus_2 | 149 |
| GSE31652 | 2012 | PSO | Ixekizumab, LS, w0/w4 (30) | HG‐U133_Plus_2 | 150 |
| GSE55201 | 2014 | PSO, NN | Ixekizumab, blood, LS, NN, w0/w2 (81) | HG‐U133_Plus_2 | 285 |
| GSE51440 | 2014 | PSO | Guselkumab, LS, NL, w0/w1/w12 (59) | HG‐U133_Plus_PM | 152 |
| GSE53552 | 2014 | PSO | Brodalumab, LS, w0/w1/w2/wq6 (99) | HG‐U133_Plus_2 | 151 |
| GSE69967 | 2016 | PSO | Tofacitinib, LS, NL, d0/1/3/w1/2/4/12 (95) | HG‐U133_Plus_2 | 286, 287 |
| GSE54456 | 2014 | PSO, NN | RNA‐seq, LS (92), NN (82) | Illumina GA | 288 |
| GSE57225 | 2014 | PSO‐AD/ACD | PSO (23), AD (10), ECZ (13), NL (16) | SurePrint G3 8x60K | 289 |
| GSE63741 | 2016 | PSO, AD, other | AD‐LS, PSO‐LS, ACD, LP, NN (30 each) | PIQOR 2.0 | 290 |
| GSE80047 | 2016 | PSO, PPP(P) | PPP (3), PPPP (6), PSO (10), NN (31) | HG‐U133_Plus_PM | 291 |
| GSE79704 | 2017 | PSO, GPP, NN | GPP‐LS (32), PSO‐LS (12), NN (20) | HG 2.1 ST | 292 |
| GSE73894 | 2017 | PSO, NN | DNA methylation, LS (135), NL (41), NN (62) | Infinium 450k | 293 |
| GSE115797 | 2018 | PSO | DNA methylation, LS (24), NL (24) | Infinium 450k | 185 |
ACD, allergic contact eczema; Dx, diagnosis; d, day; epi, epidermis; ECZ, eczema (non‐atopic); GPP, generalized pustular psoriasis; LCM, laser‐capture microdissection; LP, lichen planus; PPP, palmoplantar pustulosis; PPPP (palmoplantar pustular psoriasis); PSO‐AD, patients co‐affected by both PSO and AD; w, week.